Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Clinical response defined by reduction of CDAI score by ≥ 100 at week 6 · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.97 [0.79, 1.2]
1 study · 220 participants
Low

Infliximab 10 mg/kg vs infliximab 20 mg/kg

Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease

It is very uncertain whether infliximab 10 mg/kg changes clinical response defined by reduction of CDAI score by ≥ 70 at week 4 compared with infliximab 20 mg/kg (very low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.78 [0.49, 1.23]
1 study · 56 participants
Very low